Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research pre...
Join us for an in-depth conversation with Chua Keng Hock as we explore the challenges, strategies, and future prospects of the biopharma industry in today'...
Using radioactive ligand binding methods, Dr. Snyder’s team found that the receptors were highly concentrated in areas of the brain involved in the s...
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting,...
These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting gly...
Biopharma’s own leaders express a declining sense of industry resilience in the latest wide-reaching survey from Cytiva. The Global Biopharma Resilie...
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...
Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...
Joining ReMY on the round were new investors Boro Capital, Supernode Ventures, MedMountain Ventures, The Triangle Tweener Fund, David Golan, and Silic...
Safety data encouraging with no graft-versus-host-disease and no neurotoxicity Updated data highlighted in podium presentation at the 17th International...
This study, conducted by experts from Aquarius Population Health Limited in London and the University of Manchester, presents valuable insights into the co...
According to a recent report by the Centers for Disease Control and Prevention (CDC), 1 in 36 children in the U.S. is diagnosed with an autism spectrum dis...
After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...
In contrast to the success of CAR T-cell therapies in liquid cancers, development for the treatment of solid tumors, including glioblastoma, has progressed...
© 2024 Biopharma Boardroom. All Rights Reserved.